Building a Computational Model to Optimize Patient Treatment
Approximately 20%-35% of patients newly diagnosed with non-small cell lung cancer (NSCLC) will have locally advanced disease, sometimes referred to as stage III NSCLC. The definitions of locally advanced disease can be complex. Generally, in these cases, the tumor may have grown into other areas close to the lung, such as the diaphragm or esophagus, or spread to nearby lymph nodes. However, the disease would not have spread to distant parts of the body. The standard treatments of locally advanced lung cancer have been surgery, chemotherapy, and radiation for many decades, but recently